Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Wait

<< Previous

Bullboard Posts

Next >>

Post by Lostchannelon May 26, 2022 4:49pm

185 Views

Post# 34710330

Wait

Been at least a yr since I posted here. This board deteriorated from the "old days" and I recognized that it would take a yr or more for any recovery of the stock. I do believe the corporation shuffle is smart. To have the good dr. focus on the science is the only path to recovery. I held my shares as I don't need the remaining value and willing to take the risk and wait it out. I will come back to this board if it returns to sensible discussions

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading